Amgen Stock - Q1 earnings on deck and technical picture ahead of report
18.06.2026 - 16:57:56 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 16:55 CET. Details in the imprint.
Amgen (US0311621009) is approaching a key date for investors, with first-quarter 2026 results due on 06/19/2026 according to a recent company post. The earnings release comes as the shares trade below their 52-week high and near important technical levels on the Nasdaq.
All news and analysis on Amgen stock
Key dates, filings and background on Amgen stock, including upcoming earnings and historical disclosures, are available on the dedicated topic page and via the company’s own investor-relations site.
Q1 2026 earnings approach
Amgen has flagged that it will publish financial results for the first quarter of 2026 on 06/19/2026, with details outlined in a recent investor communication referenced on its official social-media channel. The company’s post points investors to its website for full information.
The upcoming report will be the first full quarterly update following the integration of Horizon Therapeutics, which Amgen completed in late 2023, and investors will watch closely for revenue growth and margin signals from the enlarged portfolio.
Chart picture and volatility
Amgen shares most recently closed at $341.66 on the Nasdaq, down 1.78% on the day, according to a Zacks market recap citing the latest trading session. The Zacks note highlights that the stock registered a steeper decline than the broader market.
Data compiled by MarketBeat show a 52-week range from $267.83 to $391.29, placing the current quote in the upper half of that band. MarketBeat’s profile also points to an average analyst rating of “Hold” and a consensus target price around $354.42.
From a purely technical perspective, the latest close leaves Amgen shares some distance below their 12-month high but comfortably above the 12-month low, suggesting a consolidating pattern ahead of the Q1 release rather than extreme volatility.
What the company sells
Amgen generates most of its revenue from innovative biopharmaceuticals, with key products including the cholesterol-lowering therapy Repatha, the osteoporosis treatment Prolia and the psoriasis drug Otezla, alongside a growing biosimilars and oncology portfolio.
Where the stock trades today
Amgen shares (US0311621009) trade on the Nasdaq at $341.66 as of 06/18/2026, 16:55 CET.
Key facts on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:55 CET): 341.66 USD
- Market cap: 183,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500, Nasdaq-100
- Next earnings date: 06/19/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
